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The 16p11.2 locus modulates brain structures common to
autism, schizophrenia and obesity
AM Maillard1,13, A Ruef2,13, F Pizzagalli1,2, E Migliavacca3,4, L Hippolyte1, S Adaszewski2, J Dukart2,5, C Ferrari6, P Conus6, K Männik3,
M Zazhytska3, V Siffredi1, P Maeder7, Z Kutalik4,8,9, F Kherif2, N Hadjikhani10,11,12, 16p11.2 European Consortium, JS Beckmann1,4,8,
A Reymond3,14, B Draganski2,5,14 and S Jacquemont1,14
Anatomical structures and mechanisms linking genes to neuropsychiatric disorders are not deciphered. Reciprocal copy number
variants at the 16p11.2 BP4-BP5 locus offer a unique opportunity to study the intermediate phenotypes in carriers at high risk for
autism spectrum disorder (ASD) or schizophrenia (SZ). We investigated the variation in brain anatomy in 16p11.2 deletion and
duplication carriers. Beyond gene dosage effects on global brain metrics, we show that the number of genomic copies negatively
correlated to the gray matter volume and white matter tissue properties in cortico-subcortical regions implicated in reward,
language and social cognition. Despite the near absence of ASD or SZ diagnoses in our 16p11.2 cohort, the pattern of brain
anatomy changes in carriers spatially overlaps with the well-established structural abnormalities in ASD and SZ. Using measures of
peripheral mRNA levels, we confirm our genomic copy number findings. This combined molecular, neuroimaging and clinical
approach, applied to larger datasets, will help interpret the relative contributions of genes to neuropsychiatric conditions by
measuring their effect on local brain anatomy.
Molecular Psychiatry (2015) 20, 140–147; doi:10.1038/mp.2014.145; published online 25 November 2014
INTRODUCTION
Copy number variants (CNVs) are major contributors to common
neuropsychiatric disorders and cognitive deficits.1 Investigations
of cohorts with specific CNVs allow the characterization of
endophenotypes2 associated with neuropsychiatric disorders,
such as autism spectrum disorder (ASD) and schizophrenia (SZ).
The 16p11.2 CNV (breakpoint 4–5, BP4-BP5, 29.6-30.2 Mb- Hg19)
phenotypes are characterized by both reciprocal and overlapping
deficits that include energy imbalance, language impairment, ASD
and SZ.3–8 Notably, both 16p11.2 deletion and duplication have
been associated with ASD, while only the duplication is enriched
in SZ cohorts.9,10 Deletion carriers present with increased head
circumference6,8 and body mass index (BMI),3,7 while duplication
carriers are at risk for microcephaly and being underweight.5
Manipulations of zebrafish embryos and mouse models suggest a
close relationship between gene dosage at this locus and brain
anatomy. Over- and under-expression of the KCDT13 gene in
zebrafish induces mirror alterations interpreted as correlates of
micro- and macrocephaly.11 Murine models mimicking 16p11.2
deletion and duplication demonstrate reciprocal regional brain
volume changes.12
The aim of this study is to identify imaging endophenotypes in
a group of 16p11.2 CNV carriers at high risk for ASD and SZ. We
investigate the effects of gene dosage, defined as the number of
genomic copies at the 16p11.2 locus on brain structure using the
state-of-the-art structural magnetic resonance imaging (MRI). We
find a correlation between gene dosage and alterations in brain
structure with diametrically opposite changes in both global
and local brain volumes that parallel specific changes in tissue
microstructure. The anatomical areas affected by gene dosage are
also key areas involved in ASD, SZ and obesity, supporting the
notion that common molecular mechanisms may be involved in
these conditions.
MATERIALS AND METHODS
Participants
The study was reviewed and approved by the local Ethics committee and
signed consents were obtained from the participants or legal representa-
tives prior to the investigation. Participants (Table 1) were taking part in a
larger phenotyping project on the deletion/duplication of the 16p11.2
region. Carriers were referred to the study by the clinical geneticist who
had initially established the genetic diagnosis in the context of a
neurodevelopmental disorder. Inclusion criteria: participants were selected
based on the presence of a 16p11.2 deletion or duplication comprising the
BP4-BP5 region. Controls were non-carriers in the same families. Exclusion
criteria: none beside an age o6 years. Seventeen participants were unable
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to complete the scan because of incompliance related to moderate or
severe intellectual disability, anxiety, significant behavioral issues or
extreme BMIs with waist circumference beyond the limit of scanning
safety standards.
All had whole genome arrays confirming either a recurrent deletion or
duplication of the BP4-BP5 region. The larger project aims at phenotyping
a European cohort of 16p11.2 rearrangement carriers. It includes
neuropsychological and behavioral assessments, medical, psychiatric and
neurological examinations.
Anthropometric measures, psychiatric and cognitive assessment
We collected anthropometric data such as height and weight to calculate
the BMI. Obesity is defined as BMI430 kgm-2 in adults and 42 standard
deviations in children.13 Underweight is considered significant o18.5 kg-
m2 and o2 standard deviations in children.13 Z-scores were computed for
all data using gender, age and geographically matched reference
population as previously described in Zufferey et al.8 Overall cognitive
functioning was measured using the Wechsler Intelligence scales
for children (WISC-IV)14 as well as the Wechsler Intelligence scale for
adults (WAIS-III).15 All assessments were performed by a board-certified
neuropsychologist. Diagnostic and Statistical Manual of Mental Disorders,
Fourth edition-text revision16 diagnoses were made by licensed psychol-
ogist and psychiatrist using history, parent report as well as the Diagnostic
Interview for Genetic Studies.17 An additional assessment was performed
to investigate prodroms of SZ using the Schizophrenia Proneness
Instrument Adult version.18 The diagnosis of ASD was established by a
certified clinician using the Autism Diagnostic Interview-Revised19 and the
Autism Diagnostic Observation Schedule.20 Of note, only two duplication
carriers were on medication: lithium, aripiprazol and valproate.
Quantitative RT-PCR
For quantitative polymerase chain reaction, 100 ng of high-quality total
RNA isolated from Epstein–Barr virus transformed lymphoblastoid cell lines
was converted to cDNA using Superscript VILO (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. Primers were designed
using PrimerExpress 2.0 software (Applied Biosystems, Foster City, CA,
USA), with default parameters except for the primer- and minimal
amplicon lengths, which were set at 17–26 bp and 60 bp respectively.
The amplification factor of each primer pair was tested using a cDNA
dilution series and only assays with amplification factors between 1.75 and
2.00 were retained. A representative set of samples was tested for genomic
contamination. Quantitative polymerase chain reaction experiments were
performed in triplicates using SYBR-Green (Roche, Basel, Switzerland) as
reporter. The reaction mixtures were prepared in 384-well plate using a
Freedom Evo robot (Tecan, Männedorf, Switzerland) and run in an ABI
7900HT sequence detection system (Applied Biosystems) using the
following conditions: 50 °C for 2 min, 95 °C for 10min, followed by 45
cycles of 95 °C for 15 s and then 60 °C for 1 min, after which dissociation
curves were established. Applicable normalization genes were included in
each experiment to enable compensation for fluctuations in expression
levels between experiments. Using SDS v2.4 software (Applied Biosystems)
the threshold and baseline values were adjusted when necessary to obtain
raw cycle threshold values. The cycle threshold values were further
analyzed using qBase plus software (Biogazelle, Zwijnaarde, Belgium),
which calculates relative expression values per sample per tested gene
upon designation of the normalization genes and corrects for the
amplification efficiency of the performed assay.
MRI Data acquisition and processing
All participants were examined on a 3T whole body scanner (Magnetom
TIM Trio, Siemens Healthcare, Erlangen, Germany) using a 12-channel RF
receive head coil and RF body transmit coil. Participants presenting with
moderate to severe clinical phenotype were unable to undergo the
scanning procedure. A total of 57 participants underwent the MRI protocol,
which included T1-weighted (T1w) and diffusion-weighted (DWI) data
acquisition. Anatomical images were acquired using a multi-echo
magnetization prepared rapid gradient echo sequence (ME-MPRAGE: 176
slices; 256 × 256 matrix; echo time (TE): TE1: 1.64ms, TE2: 3.5 ms, TE3:
5.36ms, TE4: 7.22ms; repetition time (TR): 2530ms; flip angle 7°). The DWI
protocol consisted of 2 mm contiguous slices covering the whole brain
(TE = 83ms, TR= 9020ms) along 60 spherically distributed gradient
directions with b-value= 700 s mm-2 with 10 reference images with no
diffusion weighting (b-value= 0 s/mm2). Due to movement of artifacts, 3
out of 57 T1w images and 5 DWI out of 45 who were able to complete the
DWI protocol were excluded.
Multi-echo T1w images were averaged then classified into probability of
belonging to gray matter (GM), white matter (WM) or cerebrospinal fluid
using Gaussian mixture model within the ‘unified segmentation’
framework.21 Images were transformed non-linearly to standard Montreal
Neurological Institute space using the diffeomorphic spatial registration
algorithm implemented in SPM8.22 GM probability maps were subse-
quently ‘modulated’ by the Jacobian determinants of the deformations to
account for local compression and expansion because of linear and non-
linear transformation.23 Finally, GM probability maps were smoothed with
an isotropic Gaussian kernel of 8 mm full-width at half-maximum.
Cortical surface extraction was performed on the averaged multi-echo
T1w images using the default settings of the Freesurfer
software (Freesurfer, Boston, MA, USA)24 (http://surfer.nmr.mgh.harvard.
edu/). Individual images were examined for potential defects of surface
reconstruction. Mean cortical thickness and cortex surface area were then
computed for each subject.
DWI images were corrected for Eddy current and motion artifacts with
the Artefact correction in diffusion MRI (ACID toolbox).25 Diffusion tensor
based indices—fractional anisotropy and mean diffusivity, were computed
with the Camino Diffusion MRI toolkit (Camino Diffusion MRI toolkit,
University College of London, UK).26 Fractional anisotropy and mean
diffusivity maps were aligned to the T1w images using affine transforma-
tion. In order to enhance the specificity for a particular tissue class and to
avoid diffusion indices value changes because of Gaussian smoothing
kernel during the spatial registration to Montreal Neurological Institute
space, we applied a previously described combined weighting/smoothing
procedure.27
For voxel-based statistical analysis of gene dosage-dependent regional
effects we used a linear regression model in the General Linear Model
framework of SPM8. Age effects were analyzed separately for GM and WM
sub-space by creating two corresponding design matrices. Explicit masking
using binary masks of GM and WM ensured inclusion of the same number
of voxels in all analyses. All GM/WM data were included in the same model
with gender, total intracranial volume (TIV) (the sum of GM, WM and
cerebrospinal fluid volume) and first-order polynomial expansion of age as
regressors. We tested for overall cognitive functioning (full-scale intellec-
tual quotient), but as results did not show significant effect on whole-brain
or regional structures, we did not add it as a covariate in the statistical
parametric mapping analyses. Statistical thresholds were applied at
Po0.05 after family-wise error correction for multiple comparisons over
the whole volume of the GM/WM mask. Trends were assessed by using an
auxiliary uncorrected voxel threshold of Po0.001.28
Multivariate linear models analysis
Multivariate linear model was used to discover high-order correlation
mapping between the two datasets: gene expression and brain volume.
The multivariate approach takes into account the full dimensionality of
both data sets (all voxels and all mRNA levels for all individuals). The
method simultaneously determines the best representations in each
Table 1. Population characteristics
Deletion
n= 14
Controls
n= 23
Duplication
n= 17
Age in years (mean± s.d.) 24.6± 13.3 33± 12.3 35.7± 12.5
Gender (M/F) 8/6 11/12 10/7
Handedness (L/R) 3/11 0/23 3/14
BMI z-score (mean ± s.d.) 2.37± 2.14a 0.37± 1.07 − 0.56± 1.61
FSIQ (mean± s.d.) 74± 14b 98± 13 72± 16b
NVIQ (mean± s.d.) 79± 11b 102± 13 73± 15b
Abbreviations: BMI, body mass index; F, female; FSIQ, full-scale intellectual
quotient; M, male; NVIQ, non-verbal intellectual quotient; L, left; R, right.
aSignificantly different from the two other groups, ANCOVA, post-hoc
group comparisons, Po0.05 Bonferroni corrected. bSignificantly different
from the control group, ANCOVA, post-hoc group comparisons, Po0.05,
Bonferroni corrected.
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datasets in order to explain maximum covariance between gene
expression and volume. The representation in the brain space is called
eigenimage and show the level contribution (either positive or negative)
for each voxel to the correlation mapping. Similarly, the gene loadings
(positive or negative) show the contribution of each gene to the
correlation mapping. The number of mappings and the significance of
the mapping is assessed with Wilks’ Lambda statistic.28,29
Statistical analyses
Statistical analyses were performed using Matlab and R 3.0.2. Plots and
heat maps have been generated using R libraries ggplot2 and gplots,
respectively.
RESULTS
Study participants and MRI measures
We acquired data on fourteen 16p11.2 BP4-BP5 deletion and
seventeen duplication carriers as well as twenty-three intrafamilial
controls. The median age of participants was 34 years (range
7–58). The three groups were not significantly different in terms of
age, gender or handedness (Table 1). Overall cognitive functioning
(full-scale intellectual quotient) in deletion and duplication carriers
was 2 standard deviations (~27 points) below that in the control
group, which is consistent with previous studies.5,8 Two duplica-
tion carriers met diagnostic criteria for ASD and none of the
participants had clinical signs of SZ (all clinical data and neuro-
radiological findings are presented in Supplementary Tables 1
and 2).
In an unbiased whole-brain approach, we analyzed regionally
derived structural MRI estimates of GM and WM volume, cortical
thickness and surface area, and also TIV.24,30 We also investigated
brain microstructure using an independent data set of DWI
images from the same subjects, from which we computed
fractional anisotropy and mean diffusivity as indices of local tissue
integrity.31 Gene dosage effects on brain anatomy were tested
explicitly over the cohorts of deletion carriers, controls and dupli-
cation carriers using differential contrasts and conjunction
analyses.
Global brain differences
We first tested the sensitivity of our whole-brain imaging
approach to detect global effects of gene dosage since early
brain overgrowth is a feature common to both ASD and the
16p11.2 deletion.8,32 We confirm the strong correlation between
head circumference and gene dosage in the studied group
(P= 0.0001)5,7 and demonstrate the negative correlation between
TIV and number of 16p11.2 copies (P= 0.004, Figure 1b). Both GM
(P= 0.009) and WM volume (P= 9.8 e-05) contribute to the
observed effect on TIV (Figures 1c and d). There is no significant
correlation between gene dosage and cerebrospinal fluid volume
suggesting that there are no compensatory cerebrospinal fluid
changes secondary to brain atrophy. The analysis of cortical
anatomy shows correlation between gene dosage and global
cortical surface area (P= 0.009, Figure 1f). As opposed to global
measures of volume and surface, which are all inter-correlated
(Figure 1a) and modulated by gene dosage, only cortical thickness
is decreased in both deletions and duplication carriers (Figures
1a–e). This may be related to previously reported relationship
between intellectual disability and cortical thickness.33,34 Of note,
adjusting for intellectual quotient does not affect our findings
(Supplementary Figure 1). Analyses on global metrics are detailed
in Supplementary Table 3.
There is a strong correlation between BMI and head circumfer-
ence in 16p11.2 CNV carriers.8 We also find a negative correlation
between BMI and gene dosage (Po0.001, Table 1). Total GM
**
* *
*
**
**
*
*
Figure 1. Effects of gene dosage on global brain metrics. (a): Correlation between global brain metrics in 16p11.2 CNV carriers and controls.
The intensity of blue lines represents positive r Pearson’s coefficient correlations at different statistical thresholds. All global measures are
inter-correlated except for CT and CSF. (b–f): Boxplots representing TIV, GM, WM volume, cortical surface area and cortical thickness adjusted
for age and gender in deletion, duplication carriers and intrafamilial controls. **P⩽ 0.001; *P⩽ 0.05 uncorrected. Gene dosage effect is
estimated in a linear regression analysis using the number of copies (1, 2 or 3), and including age, gender as covariates. Significant differences
between groups after Bonferroni correction (threshold at Po0.01) are represented by solid black lines, trends—by dashed lines. HC, head
circumference; TIV, total intracranial volume; GM, gray matter; WM, white matter; CSF, cerebrospinal fluid; CT, cortical thickness; CS, cortical
surface area; DEL, deletion carriers; CTRL, intrafamilial controls; DUP, duplication carriers.
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volume (P= 0.008) and TIV (P= 0.019) are correlated to BMI
(Supplementary Table 4) and this relationship becomes borderline
significant (P= 0.06) after adjusting for the copy number effect
on BMI.
Regional volume brain differences
Using the same statistical design and voxel-based morphometry,
we analyzed local GM and WM changes beyond global volume
effects. The spatial pattern of gene dosage-associated changes
overlaps with key areas of the reward system including the medio-
dorsal thalamus, insula, ventral striatum, orbito-frontal cortex and
WM corresponding to fronto-striatal projections (Figures 2a and c).
The language circuitry, comprising the left-middle temporal gyrus,
bilateral supramarginal and superior temporal gyri and adjacent
WM connections, also shows strong gene dosage dependence
(Figures 2a–c and Supplementary Table 5). We further observe
gene dosage effects on cerebellar anatomy, including lobules VIIb,
VIII and crus II bilaterally (Figure 2b). Subsequent gender-by-gene
dosage interaction analysis demonstrates that this effect is mainly
driven by decreased volume in male deletion carriers (Supple-
mentary Figure 2). The analysis of an independent dataset of DWI
images sensitive to water diffusion properties of brain tissue in a
subset of 45 participants confirms a reciprocal gene dosage effect
on reward and language circuit associated regions—striatum,
middle and superior temporal gyrus (Figures 2e and f). The
changes of diffusion-tensor-derived indices (fractional anisotropy
and mean diffusivity) suggest a dosage-dependent effect on brain
microstructure beyond the volume changes already described.35
We further investigated the contribution of the deletion and
duplication to the gene dosage analysis (deletion4control4
duplication) results on the brain structure. We performed a
conjunction analysis testing the intersection of the two differential
contrasts: (deletion4control)∩ (control4duplication) (Supple-
mentary Figure 3). This stringent analysis shows that both the
deletion and duplication contribute to the negative correlation
between gene dosage and putamen volume. The two differential
contrasts suggest that changes in the reward system are driven by
the duplication, while deletion carriers contribute to modifica-
tions in language and social cognition networks (Supplementary
Figure 3 and Supplementary Table 5). Due to the stringency of the
conjunction analysis, we cannot exclude rejecting modest brain
changes following the gene dosage-dependent pattern. A larger
sample size would be required to identify brain anatomy changes
specific to either deletion or duplication carriers.
Regional cortical thickness and surface area differences
We observed cortical thickness changes mainly driven by deletion
carriers in the fronto-temporal regions, particularly in insula,
supramarginal and superior temporal gyrus (Supplementary Table
6 and Supplementary Figure 4). These regions overlap spatially
with the cortical volume changes derived in the whole-brain
voxel-based morphometry analysis. For measures of cortical
surface area, the overlap is restricted to the frontal pole.
16p11.2 dosage-related brain alterations common to idiopathic
ASD and SZ
The 16p11.2 CNVs that confer high risk for ASD and SZ, exemplify
the concept of shared genetic factors in psychiatric disorders. We
formally tested the spatial overlap between the described brain
patterns and the results of a recent meta-analysis in ASD and SZ
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Figure 2. Effects of gene dosage on local brain volume and tissue properties. Results of voxel-based whole-brain general linear analyses
showing: (a) negative gene dosage effect (DEL4CTRL4DUP) on GM volume in ventral striatum, thalamus, superior temporal region, fusiform,
precuneus, insula and calcarine sulci bilaterally as well as in right occipital region. (b) Positive gene dosage effect (DELoCTRLoDUP) on GM
volume in the middle temporal gyrus and in cerebellar lobule VIII, VIIb and crus II. (c) Negative gene dosage effect on WM volume within
fronto-striatal projections, anterior thalamic and superior longitudinal fasciculus. (d) Absence of significant positive gene dosage effect on WM
volume. (e and f) FA and MD changes overlapping with GM changes in superior temporal gyrus and caudate bilaterally. For representation
purposes, results significant at a voxel level at threshold of Po0.05 family-wise error corrected for multiple comparisons are displayed at
significance threshold of Po0.001 uncorrected at voxel level in standard Montreal Neurological Institute space. Color bars represent T scores.
DEL, deletion carriers; CTRL, intrafamilial controls; DUP, duplication carriers; GM, gray matter; WM, white matter; FA, fractional anisotropy; MD,
mean diffusivity.
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brain morphometry36 (Figure 3). Areas subject to strong 16p11.2
gene dosage effects overlap with six out of the eight brain
structures most commonly affected in ASD and SZ—left and right
putamen, insula, posterior cingulate, thalamus and superior
temporal gyrus, but with none of the SZ-specific regions36
(Figure 3 and Supplementary Table 7).
mRNA expression levels and brain anatomy
16p11.2 BP4-BP5 CNVs either delete or duplicate 28 genes. We
therefore tested whether the effects of gene dosage on brain
anatomy are mediated by changes in gene expression measured
in lymphoblastic cell lines of twenty-seven of our participants. We
investigated in a linear regression analysis, mRNA levels of
eighteen genes mapping within and one gene (SH2B1) outside
the BP4-BP5 interval. While SH2B1 expression is not affected by
changes in copies of the BP4-BP5 CNVs, mRNA levels for all
eighteen genes within the interval are correlated to the number of
genomic copies and twelve of these genes show strong
correlation (Pearson r40.75) with each other (Supplementary
Figure 5).
mRNA levels of all assessed genes within the BP4-BP5 interval
except GDPD3 and PRRT2 show negative correlation with global
metrics of brain volume (Figure 4a and Supplementary Table 8). To
characterize the differential contributions of highly correlated
gene expression levels on brain structure, we performed whole-
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Figure 3. Spatial mapping of meta-analysis data in autism spectrum disorder and schizophrenia on to 16p11.2 gene dosage brain pattern.
Projection of meta-analysis data in ASD and SZ36 on the statistical map of 16p11.2 gene dosage effects on gray matter volume in deletion and
duplication carriers (DEL4CTRL4DUP). Pie charts represent previously published data on the relative contribution of ASD and SZ to brain
volume change at particular location.36 Orange-blue pie charts indicate gray matter decreases; cyan-green pie charts show gray matter
increases in ASD and SZ. Coordinates correspond to Montreal Neurological Institute standard space. ASD, autism spectrum disorder;
SZ, schizophrenia; STS, superior temporal sulcus.
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Figure 4. Effects of mRNA levels on global and local metrics of brain anatomy. Brain anatomy changes explained by mRNA levels of 18 genes
within the 16p11.2 BP4-BP5 interval in a subset of 27 participants. (a) Matrix correlation between mRNA levels and global measures of brain
volume. The color key represents the Pearson correlation coefficient. Most mRNA levels, except for SH2B1, PRRT2 and GDPD3 are correlated to
TIV, GM and WM. There are no correlations with cortical thickness and CSF. Statistical P values for all correlations are detailed in Supplementary
Table 7. (b-c) Eigenimages represent the statistical parametric maps resulting from singular value decomposition analysis. This method
simultaneously determines the best combination in each dataset (gene expression and voxels) in order to explain maximum covariance
between gene expression and local brain volume. Negative loading indicate that low mRNA levels are associated with increased GM volumes
while positive loading represents the inverse effect. TIV, total intracranial volume; GM, gray matter; WM, white matter; CSF, cerebrospinal fluid;
CS, cortical surface area; CT, cortical thickness.
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brain multivariate analyses based on singular value decomposi-
tion. This method identifies the linear combination of brain voxels
—eigenimages—that are best predicted by a linear mixture of
gene expression levels. Despite the reduced subject sample size,
this analysis replicated the anatomical pattern described by
categorical analyses of gene dosage effects (Figures 2 and 4). The
first eigenimage is characterized by negative loadings on the
striatum, fusiform gyrus and thalamus bilaterally (Figure 4b), as
well as positive loadings on both cerebellar hemispheres
(Figure 4c). Put simply, voxels with negative loadings indicate
that low mRNA levels are associated with increased GM volumes
while those with positive loadings with GM volume reduction. In
our cohorts, the first three eigenimages explain more than 30% of
variance in brain anatomy, and are mainly driven by the number
of genomic copies (P= 0.003, 0.01 and 0.07 for the first three
eigenvariates, respectively). The correlation between gene expres-
sion and the number of genomic copies (Supplementary Figure 5)
as well as the high level of shared variance between genes at this
locus preempts identification of the contributions of individual
gene to specific anatomical patterns (Supplementary Table 9 and
Figure 6).
DISCUSSION
Using an unbiased whole-brain approach, we demonstrate that
genomic copy number at the 16p11.2 BP4-BP5 locus is associated
with brain anatomy changes in a dosage-dependent manner, and
that these structural changes are present in the absence of either
an ASD or SZ diagnosis. Our findings including areas implicated in
reward, language and social cognition allow generating new
hypotheses on how gene dosage results in reciprocal and
overlapping phenotypes observed in 16p11.2 deletion and
duplication carriers. This provides a general framework to study
the effects of CNV on cognition and behavior in common
neuropsychiatric disorders such as ASD and SZ. This approach
circumvents a number of confounders such as the effects of
ascertainment, medication and clinical symptoms2,37 and has
recently been used to investigate predefined anatomical regions
related to early psychosis in 15q11.2 CNVs carriers.38
There is a strong correspondence between the changes in brain
anatomy patterns and the phenotypic traits characterizing
16p11.2 deletion or duplication carriers. In particular, opposing
volume changes in key nodes of the reward circuitry—striatum,
medio-dorsal thalamus, orbito-frontal cortex and insula—which
are associated with eating behavior,39–41 may explain the mirror
BMI phenotype in 16p11.2 CNVs carriers. Similarly, the reciprocal
changes in the language areas—middle, superior temporal gyrus
and caudate42 may underlie the language deficits reported in
deletion but not in duplication carriers. Our results showing
involvement of the striatum have recently been corroborated by
the findings of Portmann et al.43 in a mouse model of 16p11.2
deletion syndrome.
Whole genome studies have identified genetic factors, includ-
ing 16p11.2 CNVs, shared between ASD and SZ. This led to the
assumption that the two disorders may represent opposite
manifestations of the same underlying mechanism or trait.44
There is a large overlap in the reported patterns of gene dosage-
dependent brain anatomy changes with well-established struc-
tural signatures of ASD and SZ. Notably, alterations in reward
system structure, influenced by 16p11.2 gene dosage, is also the
main structural change shared by ASD and SZ.36,45,46 This finding
supports the notion of a common abnormal mechanism under-
lying these two conditions. None of the studied participants met
diagnostic criteria for SZ and only two did so for ASD
(Supplementary Table 1), which suggests that the observed brain
modifications are not the consequence of a long standing ASD or
SZ diagnosis, but that they may be considered as intermediate
phenotypes. This is also in keeping with previous findings of brain
modifications predating the onset of psychosis.47
Obesity is a well-known comorbidity of ASD or SZ.48 It has been
hypothesized that the reward system, and the striatum in
particular, may underlie the frequent co-occurrence of metabolic
and psychiatric manifestations.37,39,41,49 This idea is in line with our
findings and suggests that modulation of the reward system by
genes at the 16p11.2 locus is driving a group of disorders as
opposed to the notion that different genes lead to different
symptoms in CNV carriers.
Analyses of cortex anatomy showed cortical thickness reduction
in 16p11.2 deletion carriers and a similar trend in duplication
carriers. This shared feature may be explained by decreased
intellectual quotient and risk for ASD in both deletion and
duplication carriers. However, both cortical thickness and surface
area are correlated to intellectual quotient and this relationship
changes with age.50 Of note, SZ is also associated with widespread
cortical thining.51 The dissociation between cortical surface and
thickness with regards to 16p11.2 gene dosage supports the
notion of distinct genetic mechanisms regulating these cortical
anatomy features.52,53 As shown in the general population and
ASD, it is most likely that the 16p11.2 gene dosage effects on brain
volume are related to changes in total cortical surface.52,54,55
Therefore, we refrain from drawing conclusions on topology
overlap and causal links between regional thickness/surface
changes and brain volume alterations.54
In agreement with the known effect of gender in ASD and in
carriers of 16p11.2 CNVs,5,56 we observe a volume reduction in
both cerebellar hemispheres restricted to male deletion carriers
(Supplementary Figure 2). This finding supports the notion of
differential neurodevelopmental effects of genetic variants in
males and females as well as mounting evidence for cerebellar
involvement in intellectual disability, language impairment and
ASD.57,58
The reciprocal effects of gene dosage on global metrics of brain
volume and cortical surface area corroborate previous reports on
head size measurements in humans and zebrafish.5,11 In the
absence of gene dosage-dependent cortical thickness changes,
we interpret the effects of 16p11.2 CNVs on brain volume and
cortical surface area as evidence of abnormal neurogenesis.59
TAOK2, MAPK3, MVP, KIF22, ALDOA and KCTD13, are 16p11.2 genes
previously linked to neurogenesis and/or apoptosis,11,60,61 and
could represent candidate genes implicated in the control of brain
growth.
Whole brain analysis using continuous measures of mRNA
levels further validates results using the number of genomic
copies (1, 2 or 3), and both approaches identify that the same
anatomical structures are involved. Given the significant amount
of shared variance between mRNA levels of the studied genes at
the 16p11.2 BP4-BP5 locus we refrain from drawing conclusions
about potential differential contribution of single genes on brain
anatomy.
One of the anticipated limitations of the study is the inability to
acquire imaging data in participants with significant behavioral
deficits and BMI/waist circumference beyond limits of MRI
scanning safety standards. Results might not generalize to other
16p11.2 CNV carriers with extreme obesity or a full-blown clinical
symptoms of ASD or SZ. Nevertheless, with respect to global
cognition, our cohort is highly representative of 16p11.2 with
intellectual quotient measures identical to what has been
previously published.4,8
CONCLUSION
In this study, we demonstrate that gene dosage at the 16p11.2
locus modulates specific neural circuitry including foremost the
reward system. The patterns of brain anatomy changes in fronto-
subcortical networks could be interpreted as endophenotypes of
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ASD, SZ and obesity associated with 16p11.2 rearrangements in
the absence of diagnostic criteria for ASD and SZ. The comple-
mentary analysis using peripheral measures of gene expression
levels brings further evidence for the correlation between gene
dosage and brain structure. This combined approach applied to
larger datasets should allow dissection of the relative contribu-
tions of genes to human behavior and cognition through a fine-
grained analysis of human brain anatomy.
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